Navigation Links
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Date:9/10/2009

WATERTOWN, Mass., Sept. 10 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

"We appreciate the opportunity to share some of the results from our work with this very powerful and ground-breaking chemistry platform," stated Mr. Guy Macdonald, President and CEO of Tetraphase Pharmaceuticals. "This enabling chemistry technology dramatically expands the chemical diversity of tetracyclines and is highly versatile, providing compounds with possibilities for IV and oral dosing routes and activity against multiple drug-resistant strains."

The oral presentation will be given in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines", as follows:

September 14(th) (9:00 a.m. - 9:15 a.m., Poster Session 142)

  • Presentation Number F1-1219 - Oral Antibacterial Activity of a Novel Pentacycline

The posters will be presented in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines" as follows:

September 14(th) (11:15 a.m. - 1:15 p.m., Poster Session 166)

  • Presentation Number F1-1514: Synthesis and Antibacterial Activities of Aza Tetracyclines: A Novel Class of Tetracycline Analogs

  • Presentation Number F1-1515: In Vitro and In Vivo Activities of Novel Broad-Spectrum 8-Aza Tetracyclines

  • Presentation Number F1-1516: Synthesis and Antibacterial Activities of Pentacyclines: A Novel Class of Tetracycline Analogs

Copies of the oral presentation and the posters will be available at ICAAC and on the Tetraphase website (www.tphase.com) following ICAAC.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
2. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
3. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
4. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
5. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
7. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
11. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):